Marie Skłodowska-Curie - Research Fellow (full-time)
[MN1] BIO-MICRO Project
Affiliation: Randox Laboratories, Clinical Immunoassay R&D, Crumlin, UK
Offer Description:
We are looking for a highly motivated and proactive researcher who is able to work both independently and collaboratively within an interdisciplinary team focussing on micronutritional therapy in patients undergoing rehabilitation for cardiac surgery. You have strong analytical and problem-solving skills, with the ability to integrate multidisciplinary data. You have excellent communication skills for disseminating research findings. You have a collaborative mindset, with experience in interdisciplinary teams (e.g., clinicians, bioinformaticians, analytical chemists). The position includes intersectoral secondments in Amsterdam University Medical Center for 12 months. The project should result in the successful completion of a PhD thesis.
What will you do
- RF8: Personalization, adequate monitoring and guidance of Micro Nutrient therapy in cardiac arrest patients Duration: 36 months
- Supervisor(s): Cecilia Fortugno, Kenneth Martin, Angelique de Man (AUMC), Kristine Koekkoek (MH)
- Enrolment in a Doctoral Program: Amsterdam UMC - Vrije Universiteit Amsterdam
Project description:
This PhD project will focus on identifying inflammation‑related biomarker combinations and data‑driven algorithms to classify cardiac arrest patient subphenotypes. Using advanced multiplex biomarker technologies, the project will support development of novel diagnostic tools to improve patient stratification and guide targeted micronutrient (MN) interventions. Randox has access to a broad and diverse biomarker multiplexing portfolio, including several novel biomarkers highly relevant to cardiac surgery and peri‑operative inflammation. The PhD will contribute to the development of clinically validated multiplex biochip products based on optimal biomarker combinations and classification algorithms. These tools will aim to take the first steps towards more personalized approaches of MN therapy. Identification of treatment responders based on the comparison of the individual inflammation responses to each intervention in the VITaCCA trial. Optimal duration of MN therapy is determined in the VITaCCA trial based on the course of the inflammatory response.
The objectives will be:
- To test in a multicenter RCT (VITaCCA), if the evaluation of a patient`s biological phenotype may be a new innovative and reliable strategy to identify treatment responders
- To compare the response of inflammation biomarkers between the vitamin C and placebo groups for identification of treatment responders
To investigate optimal timing of vitamin C therapy based on the inflammation biomarkers
-
To be eligible for this position, applicants must meet the Marie Skłodowska-Curie admission requirements:
- You must not already hold a doctoral degree.
- You must comply with the MSCA mobility rule: you must not have resided in or carried out your main activity (work, studies, etc.) in the UK for more than 12 months during the three years immediately prior to recruitment.
In addition, you meet the following requirements and experience:
Essential criteria
- A Master’s degree in a relevant discipline such as biomedical science, biochemistry, immunology, molecular biology, bioengineering, data science, or a related field
